Amarin (AMRN) FDA Acceptance for Filing of AMR101 NDA
Welcome to CRWENewswire, Stocks to Watch. I am Shalika Jayasekera. Amarin Corporation plc – symbol AMRN – reported that its New Drug Application for AMR101 has been accepted for filing by the FDA. Amarin is developing AMR101 for the treatment of patients with very high triglyceride levels and as a potentially first-in-class therapy for patients with high triglyceride levels who are also on statin therapy for elevated LDL-cholesterol levels. Triglycerides are a type of fat in the blood. Persons with a high triglyceride level often have other conditions such as diabetes and obesity that also increase the chances of developing heart disease. Amarin Corporation is a late-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. Thanks for joining me and have a great day! For CRWE Newswire, Stocks to watch, I’m Shalika Jayasekera
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (Read more at http://www.crwenewswire.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.